Le Lézard
Classified in: Health, Science and technology
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Ceapro to Participate in the Virtual Investor Summer Spotlight Series


EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (ceapro.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company's website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]

Issuer:

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



These press releases may also interest you

at 16:42
Karman Space & Defense Launches New Website & Tagline
Karman Space & Defense ("Karman"), a concept-to-production solutions provider for the most complex challenges in our industry, proudly announces the launch of its captivating, newly redesigned website, and bold tagline "Impossible Ends Here."...

at 16:35
Nordson Corporation Reports Second Quarter Fiscal 2024 Results and Updates Annual Guidance
Nordson Corporation today reported results for the fiscal second quarter ended April 30, 2024. Sales were $651 million, comparable to the prior year's second quarter sales of $650 million. The second quarter 2024 sales included a favorable...

at 16:30
SHI International Corp. Announces Definitive Agreement to Acquire Locuz Enterprise Solutions Limited, an Indian Cybersecurity and Digital Transformation Services Company
SHI International Corp., a leading global provider of innovative technology solutions, today announced that it has entered into a definitive agreement to acquire Locuz Enterprise Solutions Limited, an Indian cybersecurity and digital transformation...

at 16:30
John Stankey to Update Shareholders at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference on May 21
Tune in at 8:10 a.m. ET on May 21 for a fireside chat with AT&T's chief executive officer, where he will cover recent progress on the company's multiyear growth strategy. Key Takeaways: AT&T continues to make progress on its sustainable, long-term...

at 16:30
SIMPSON MANUFACTURING CO., INC. ANNOUNCES UDIT MEHTA AS CHIEF TECHNOLOGY OFFICER
Simpson Manufacturing Co., Inc. (the "Company") , an industry leader in engineered structural connectors and building solutions, today announced Udit Mehta has joined the Company as Chief Technology Officer, effective May 10, 2024....

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

More news about Science and technology...


News published on and distributed by: